# Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)

> **NCT06698198** · PHASE1 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 175 (actual)

## Conditions studied

- Pneumococcal Immunization

## Interventions

- **BIOLOGICAL:** Pneumococcal Conjugate Vaccine
- **BIOLOGICAL:** Prevnar 13®

## Key facts

- **NCT ID:** NCT06698198
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-03
- **Primary completion:** 2019-09-30
- **Final completion:** 2019-09-30
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06698198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06698198, "Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06698198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*